Blood Cancer Talks cover image

Episode 15. Management of Newly Diagnosed DLBCL (Including Bonus ASH22 Updates)

Blood Cancer Talks

00:00

The Polarix Trial: A Multi-Million Dollar Question

If the FDA approves polytuzumab would you swap to using polar chip for the upfront treatment of DOECL for all your DOBC patients? For some of you do be a patient for none of them, how would you think about this trial? Yeah so that is a very tough question honestly. I'm going to deserve it for patients who I think have high risk disease in the future once it gets approved. But does every patient need it? If I have a patient who has low risk disease, NC-C and IPI score of 0 to 1 where their outcomes with our chopper are already 5 year overall survival PFS of 80%. It's the patients who have very

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app